

OPHTHALMIC THERAPEUTIC DRUGS: TECHNOLOGIES AND GLOBAL MARKETS



PHM031D
July 2015

Dr. Cheryl Lee Barton
Project Analyst

ISBN: 1-62296-123-4



BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481 USA
866-285-7215 (toll-free within the USA),
or (+1) 781-489-7301
www.bccresearch.com
information@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY GOALS AND OBJECTIVES	2
REASONS FOR DOING THE REPORT	2
SCOPE OF REPORT	2
INTENDED AUDIENCE	3
METHODOLOGY AND INFORMATION SOURCES	3
ANALYST'S CREDENTIALS	3
RELATED REPORTS	3
BCC RESEARCH WEBSITE	4
DISCLAIMER	4
CHAPTER 2 SUMMARY	6
<i>SUMMARY TABLE GLOBAL OPHTHALMIC THERAPEUTIC DRUG MARKET BY SEGMENT, THROUGH 2019 (\$ MILLIONS)</i>	7
<i>SUMMARY FIGURE GLOBAL OPHTHALMIC THERAPEUTIC DRUG MARKET BY SEGMENT, 2013-2019 (\$ MILLIONS)</i>	8
CHAPTER 3 RETINAL DISEASES: AGE-RELATED MACULAR DEGENERATION	10
RETINAL DISEASE	10
<i>FIGURE 1 STRUCTURE OF THE EYE</i>	10
AGE-RELATED MACULAR DEGENERATION (AMD)	11
<i>FIGURE 2 AMD ADDRESSABLE PATIENT POPULATION (NUMBERS)</i>	11
DISEASE SUBTYPES	12
Early AMD	12
Intermediate AMD	12
Late-Stage AMD	12
Dry AMD	12
Wet AMD	13
<i>FIGURE 3 PHYSIOLOGICAL CHANGES IN WET AND DRY AMD</i>	13
DIAGNOSIS RATE	14
CURRENT TREATMENT	14
<i>TABLE 1 PRODUCTS APPROVED TO TREAT WET AMD</i>	15
CURRENT MARKET SIZE	15
<i>TABLE 2 GLOBAL AMD SALES OF APPROVED PRODUCTS BY DRUG, THROUGH 2019 (\$ MILLIONS)</i>	15
<i>TABLE 3 GLOBAL AMD SALES OF APPROVED PRODUCTS BY DRUG CLASS, THROUGH 2019 (\$ MILLIONS)</i>	16
<i>TABLE 4 GLOBAL AMD SALES OF APPROVED PRODUCTS BY COMPANY, THROUGH 2019 (\$ MILLIONS)</i>	16
<i>FIGURE 4 GLOBAL MARKET SHARE OF AMD APPROVED PRODUCTS BY COMPANY, 2014 (%)</i>	16
MARKET DRIVERS	17
AREAS OF UNMET CLINICAL NEED	18
<i>TABLE 5 AREAS OF UNMET CLINICAL NEED IN AMD TREATMENT</i>	18
NEW THERAPIES FOR WET AMD	18
CONBERCEPT (CHENGDU KANGHONG PHARMACEUTICAL GROUP)	19
LAMPALIZUMAB (GENENTECH)	19

TOPIC	PAGE NO.
BROLUCIZUMAB (ALCON)	20
FOVISTA + ANTI-VEGF COMBINATION (ALCON/OPHTHOTECH)	20
TABLE 6 PRODUCTS IN DEVELOPMENT FOR WET AMD - PHASE III	21
TABLE 7 PRODUCTS IN DEVELOPMENT FOR WET AMD - PHASE II	21
TABLE 8 PRODUCTS IN DEVELOPMENT FOR WET AMD - PHASE I	23
NEW TREATMENTS FOR DRY AMD	23
TABLE 9 PRODUCTS IN DEVELOPMENT FOR DRY AMD - PHASE III	23
TABLE 10 PRODUCTS IN DEVELOPMENT FOR DRY AMD - PHASE II	24
NEW THERAPIES	24
Emixustat Hydrochloride (Acucela/Otsuka)	24
FIGURE 5 MECHANISM OF ACTION OF ACUCLEA'S VCMS	25
GSK-933776 (GSK)	25
FUTURE MARKET SIZE	25
TABLE 11 GLOBAL AMD SALES OF PIPELINE PRODUCTS, THROUGH 2019 (\$ MILLIONS)	25
TABLE 12 GLOBAL AMD SALES OF APPROVED AND PIPELINE PRODUCTS, THROUGH 2019 (\$ MILLIONS)	27
SUMMARY	28
CHAPTER 4 GLAUCOMA	30
FIGURE 6 GLAUCOMA ADDRESSABLE PATIENT POPULATION (NUMBERS)	30
DISEASE SUBTYPES	31
PRIMARY OPEN-ANGLE GLAUCOMA	31
PRIMARY ANGLE-CLOSURE GLAUCOMA	31
FIGURE 7 SCHEMATIC OF OPEN AND CLOSED ANGLE GLAUCOMA	31
DIAGNOSIS RATE	32
CURRENT TREATMENT	33
TABLE 13 APPROVED GLAUCOMA DRUG CHARACTERISTICS	33
MONOTHERAPY	34
TABLE 14 PRODUCTS APPROVED TO TREAT GLAUCOMA - MONOTHERAPY	34
FIXED DOSE COMBINATIONS	35
TABLE 15 PRODUCTS APPROVED TO TREAT GLAUCOMA - FIXED DOSE COMBINATIONS	35
Prescription Patterns	35
FIGURE 8 PRESCRIPTION DRUG CLASSES IN THE U.S., 2013 (%)	35
FIGURE 9 PRESCRIPTION DRUG CLASSES IN EUROPE, 2013 (%)	36
FIGURE 10 PRESCRIPTION DRUG CLASSES IN JAPAN, 2010 (%)	37
CURRENT MARKET SIZE	38
TABLE 16 GLOBAL GLAUCOMA SALES OF APPROVED PRODUCTS, THROUGH 2019 (\$ MILLIONS)	38
TABLE 17 GLOBAL GLAUCOMA SALES OF APPROVED PRODUCTS BY DRUG CLASS, THROUGH 2019 (\$ MILLIONS)	40
FIGURE 11 GLOBAL MARKET SHARE OF GLAUCOMA APPROVED PRODUCTS BY DRUG CLASS, 2014 (%)	41
TABLE 18 GLOBAL GLAUCOMA SALES OF APPROVED PRODUCTS BY COMPANY, THROUGH 2019 (\$ MILLIONS)	42
FIGURE 12 GLOBAL MARKET SHARE OF GLAUCOMA APPROVED PRODUCTS BY COMPANY, 2014 (%)	42
MARKET DRIVERS	43

TOPIC	PAGE NO.
AREAS OF UNMET CLINICAL NEED	43
TABLE 19 AREAS OF UNMET CLINICAL NEED IN GLAUCOMA TREATMENT	44
NEW DELIVERY APPROACHES AND FORMULATIONS	44
TABLE 20 PRODUCTS IN DEVELOPMENT TO TREAT GLAUCOMA - PHASE III	45
TABLE 21 PRODUCTS IN DEVELOPMENT TO TREAT GLAUCOMA - PHASE II	46
TABLE 22 PRODUCTS IN DEVELOPMENT TO TREAT GLAUCOMA - PHASE I	47
NEW THERAPIES	47
RHO KINASE (ROCK) INHIBITORS	48
GLANATEC (KOWA)	48
RHOPRESSA AND ROCLATAN (AERIE PHARMACEUTICALS)	48
FIGURE 13 QUADRUPLE MODE OF ACTION OF AERIE PHARMACEUTICALS' RHOPRESSA	48
TABLE 23 ROCK INHIBITORS IN DEVELOPMENT	50
GENE SILENCING AGENTS	50
TABLE 24 GENE SILENCING AGENTS IN DEVELOPMENT	50
BAMOSIRAN (SYLENTIS SA)	50
IST-0036 (ISARNA THERAPEUTICS GMBH)	51
QPI-1007 (QUARK PHARMACEUTICALS)	51
EARLY-STAGE DRUG DEVELOPMENT	52
ANTI-AMYLOID BETA AGENTS	52
CANNABINOIDS	52
TRANSIENT RECEPTOR POTENTIAL VANILLOID ISOFORM 4 (TRPV4)	52
FUTURE MARKET SIZE	53
TABLE 25 GLOBAL GLAUCOMA SALES OF PIPELINE PRODUCTS, THROUGH 2019 (\$ MILLIONS)	53
TABLE 26 GLOBAL GLAUCOMA SALES OF APPROVED AND PIPELINE PRODUCTS, THROUGH 2019 (\$ MILLIONS)	55
SUMMARY	55
CHAPTER 5 DRY EYE SYNDROME	58
FIGURE 14 DRY EYE SYNDROME ADDRESSABLE PATIENT POPULATION (NUMBERS)	58
DIAGNOSIS RATE	59
CURRENT TREATMENT	59
TABLE 27 PRODUCTS APPROVED TO TREAT DES	60
CURRENT MARKET SIZE	60
TABLE 28 GLOBAL DES SALES OF APPROVED PRODUCTS, THROUGH 2019 (\$ MILLIONS)	61
TABLE 29 GLOBAL DES SALES OF APPROVED PRODUCTS BY DRUG CLASS, THROUGH 2019 (\$ MILLIONS)	62
FIGURE 15 GLOBAL MARKET SHARE OF DES APPROVED PRODUCTS BY DRUG CLASS, 2014 (%)	62
TABLE 30 GLOBAL DES SALES OF APPROVED PRODUCTS BY COMPANY, THROUGH 2019 (\$ MILLIONS)	64
FIGURE 16 GLOBAL MARKET SHARE OF DES APPROVED PRODUCTS BY COMPANY, 2014 (%)	64
MARKET DRIVERS	65
AREAS OF UNMET CLINICAL NEED	65
TABLE 31 AREAS OF UNMET CLINICAL NEED IN DES TREATMENT	66
NEW THERAPIES	66

TOPIC	PAGE NO.
CYCLOKAT/IKERVIS (SANTEN PHARMACEUTICAL)	66
LIFITEGRAST (SHIRE)	66
REFRESH (ACTAVIS)	67
EBI-005 (ELEVEN BIOTHERAPEUTICS)	67
EGP-435 (EYEGATE PHARMA/VALEANT PHARMACEUTICALS)	67
MIM-D3 (MIMETOGEN)	67
<i>TABLE 32 PRODUCTS IN DEVELOPMENT TO TREAT DES - PHASE III</i>	68
<i>TABLE 33 PRODUCTS IN DEVELOPMENT TO TREAT DES - PHASE II</i>	68
NEW FORMULATIONS	69
EARLY-STAGE DRUG DEVELOPMENT	69
FUTURE MARKET SIZE	69
<i>TABLE 34 GLOBAL DES SALES OF PIPELINE PRODUCTS, THROUGH 2019 (\$ MILLIONS)</i>	70
<i>TABLE 35 GLOBAL DES SALES OF APPROVED AND PIPELINE PRODUCTS, THROUGH 2019 (\$ MILLIONS)</i>	71
SUMMARY	71
CHAPTER 6 UVEITIS	73
<i>FIGURE 17 UVEITIS ADDRESSABLE PATIENT POPULATION (NUMBERS)</i>	73
DIAGNOSIS RATE	74
CURRENT TREATMENT	75
<i>TABLE 36 PRODUCTS APPROVED TO TREAT UVEITIS</i>	75
CURRENT MARKET SIZE	75
<i>TABLE 37 GLOBAL UVEITIS SALES OF APPROVED PRODUCTS, THROUGH 2019 (\$ MILLIONS)</i>	76
<i>TABLE 38 GLOBAL UVEITIS SALES OF APPROVED PRODUCTS BY DRUG CLASS, THROUGH 2019 (\$ MILLIONS)</i>	76
<i>FIGURE 18 GLOBAL MARKET SHARE OF UVEITIS APPROVED PRODUCTS BY DRUG CLASS, 2014 (%)</i>	76
<i>TABLE 39 GLOBAL UVEITIS SALES OF APPROVED PRODUCTS BY COMPANY, THROUGH 2019 (\$ MILLIONS)</i>	78
<i>FIGURE 19 GLOBAL MARKET SHARE OF UVEITIS APPROVED PRODUCTS BY COMPANY, 2014 (%)</i>	78
MARKET DRIVERS	79
AREAS OF UNMET CLINICAL NEED	79
<i>TABLE 40 AREAS OF UNMET CLINICAL NEED IN UVEITIS TREATMENT</i>	79
NEW THERAPIES	80
GEVOKIZUMAB (XOMA)	80
SIROLIMUS (SANTEN PHARMACEUTICAL)	80
<i>TABLE 41 PRODUCTS IN DEVELOPMENT TO TREAT UVEITIS - PHASE III</i>	81
<i>TABLE 42 PRODUCTS IN DEVELOPMENT TO TREAT UVEITIS - PHASE II</i>	81
<i>TABLE 43 PRODUCTS IN DEVELOPMENT TO TREAT UVEITIS - PHASE I</i>	82
NEW FORMULATIONS	82
EGP-437 (EYEGATE PHARMA/ VALENAT PHARMACUETICALS)	82
EARLY-STAGE DRUG DEVELOPMENT	83
FUTURE MARKET SIZE	83
<i>TABLE 44 GLOBAL UVEITIS SALES OF PIPELINE PRODUCTS, THROUGH 2019 (\$ MILLIONS)</i>	83

TOPIC	PAGE NO.
<i>TABLE 45 GLOBAL UVEITIS SALES OF APPROVED AND PIPELINE PRODUCTS, THROUGH 2019 (\$ MILLIONS)</i>	85
SUMMARY	85
CHAPTER 7 RECENT MARKET ACTIVITY	87
ALLIANCES AND LICENSING DEALS	87
<i>FIGURE 20 OPHTHALMIC ALLIANCE AND LICENSING DEALS BY YEAR, 2007-2014 (NO. OF DEALS)</i>	87
<i>FIGURE 21 OPHTHALMIC ALLIANCE AND LICENSING DEALS BY TERRITORY, 2007-2014 (NO. OF DEALS)</i>	87
<i>TABLE 46 LEADING OPHTHALMIC DEALS IN THE U.S. BASED ON VALUE, 2007-JULY 2015 (\$ MILLIONS)</i>	89
<i>TABLE 47 LEADING OPHTHALMIC DEALS IN ASIA BASED ON VALUE, 2007-2014 (\$ MILLIONS)</i>	90
<i>TABLE 48 LEADING OPHTHALMIC DEALS IN EUROPE BASED ON VALUE, 2007-2014 (\$ MILLIONS)</i>	91
ALLIANCES AND LICENSING DEALS BY THERAPEUTIC CATEGORY	91
<i>FIGURE 22 OPHTHALMIC ALLIANCES AND LICENSING DEALS BY THERAPEUTIC CATEGORY, 2007-2014 (NO. OF DEALS)</i>	91
<i>TABLE 49 LEADING OPHTHALMIC DEALS IN AMD BASED ON VALUE, 2007-2014 (\$ MILLIONS)</i>	93
<i>TABLE 50 LEADING OPHTHALMIC DEALS IN RETINOPATHY BASED ON VALUE, 2007-2014 (\$ MILLIONS)</i>	95
<i>TABLE 51 LEADING OPHTHALMIC DEALS IN GLAUCOMA BASED ON VALUE, 2007-2014 (\$ MILLIONS)</i>	96
MERGERS AND ACQUISITIONS	96
<i>FIGURE 23 OPHTHALMIC MERGERS AND ACQUISITIONS BY YEAR, 2007-2014 (NUMBER)</i>	96
<i>TABLE 52 RECENT ACQUISITIONS IN THE OPHTHALMIC ARENA BASED ON VALUE, 2007- JULY 2015 (\$ MILLIONS)</i>	98
CHAPTER 8 COMPANY PROFILES	101
LEADING PHARMACEUTICALS COMPANIES	101
ACTAVIS (FORMERLY ALLERGAN)	101
ALCON	101
F. HOFFMANN-LA ROCHE	102
MERCK & CO.	103
SHIRE PLC	104
SUMITOMO DAINIPPON PHARMA	104
VALEANT PHARMACEUTICALS	105
LEADING SPECIALIST PHARMA COMPANIES	106
ACUCELA	106
AERIE PHARMACEUTICALS	106
INOTEK PHARMACEUTICALS	107
LUX BIOSCIENCES	107
MOLECULAR PARTNERS AG	108
OPTHERION PHARMACEUTICALS	108
PSIVIDA CORPORATION	109
REGENERON PHARMACEUTICALS	109
RESOLVYX PHARMACEUTICALS	110

TOPIC	PAGE NO.
SANTEN PHARMACEUTICAL CO. LTD	110
SYLENTIS S.A.	111
LEADING GENERIC AND BIOSIMILAR MANUFACTURER	111
AKORN INC.	111
CHAPTER 9 APPENDIX I: ACRONYMS	113
ACRONYMS	113
CHAPTER 10 APPENDIX II: REFERENCES	115
AMD REFERENCES	115
GLAUCOMA REFERENCES	116
DRY EYE SYNDROME REFERENCES	119
UVEITIS REFERENCES	120
WEBSITES	120
WEBLINKS	121

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE GLOBAL OPHTHALMIC THERAPEUTIC DRUG MARKET BY SEGMENT, THROUGH 2019 (\$ MILLIONS)	7
TABLE 1 PRODUCTS APPROVED TO TREAT WET AMD	15
TABLE 2 GLOBAL AMD SALES OF APPROVED PRODUCTS BY DRUG, THROUGH 2019 (\$ MILLIONS)	15
TABLE 3 GLOBAL AMD SALES OF APPROVED PRODUCTS BY DRUG CLASS, THROUGH 2019 (\$ MILLIONS)	16
TABLE 4 GLOBAL AMD SALES OF APPROVED PRODUCTS BY COMPANY, THROUGH 2019 (\$ MILLIONS)	16
TABLE 5 AREAS OF UNMET CLINICAL NEED IN AMD TREATMENT	18
TABLE 6 PRODUCTS IN DEVELOPMENT FOR WET AMD - PHASE III	21
TABLE 7 PRODUCTS IN DEVELOPMENT FOR WET AMD - PHASE II	21
TABLE 8 PRODUCTS IN DEVELOPMENT FOR WET AMD - PHASE I	23
TABLE 9 PRODUCTS IN DEVELOPMENT FOR DRY AMD - PHASE III	23
TABLE 10 PRODUCTS IN DEVELOPMENT FOR DRY AMD - PHASE II	24
TABLE 11 GLOBAL AMD SALES OF PIPELINE PRODUCTS, THROUGH 2019 (\$ MILLIONS)	25
TABLE 12 GLOBAL AMD SALES OF APPROVED AND PIPELINE PRODUCTS, THROUGH 2019 (\$ MILLIONS)	27
TABLE 13 APPROVED GLAUCOMA DRUG CHARACTERISTICS	33
TABLE 14 PRODUCTS APPROVED TO TREAT GLAUCOMA - MONOTHERAPY	34
TABLE 15 PRODUCTS APPROVED TO TREAT GLAUCOMA - FIXED DOSE COMBINATIONS	35
TABLE 16 GLOBAL GLAUCOMA SALES OF APPROVED PRODUCTS, THROUGH 2019 (\$ MILLIONS)	38
TABLE 17 GLOBAL GLAUCOMA SALES OF APPROVED PRODUCTS BY DRUG CLASS, THROUGH 2019 (\$ MILLIONS)	40
TABLE 18 GLOBAL GLAUCOMA SALES OF APPROVED PRODUCTS BY COMPANY, THROUGH 2019 (\$ MILLIONS)	42
TABLE 19 AREAS OF UNMET CLINICAL NEED IN GLAUCOMA TREATMENT	44
TABLE 20 PRODUCTS IN DEVELOPMENT TO TREAT GLAUCOMA - PHASE III	45
TABLE 21 PRODUCTS IN DEVELOPMENT TO TREAT GLAUCOMA - PHASE II	46
TABLE 22 PRODUCTS IN DEVELOPMENT TO TREAT GLAUCOMA - PHASE I	47
TABLE 23 ROCK INHIBITORS IN DEVELOPMENT	50
TABLE 24 GENE SILENCING AGENTS IN DEVELOPMENT	50
TABLE 25 GLOBAL GLAUCOMA SALES OF PIPELINE PRODUCTS, THROUGH 2019 (\$ MILLIONS)	53
TABLE 26 GLOBAL GLAUCOMA SALES OF APPROVED AND PIPELINE PRODUCTS, THROUGH 2019 (\$ MILLIONS)	55
TABLE 27 PRODUCTS APPROVED TO TREAT DES	60
TABLE 28 GLOBAL DES SALES OF APPROVED PRODUCTS, THROUGH 2019 (\$ MILLIONS)	61
TABLE 29 GLOBAL DES SALES OF APPROVED PRODUCTS BY DRUG CLASS, THROUGH 2019 (\$ MILLIONS)	62
TABLE 30 GLOBAL DES SALES OF APPROVED PRODUCTS BY COMPANY, THROUGH 2019 (\$ MILLIONS)	64
TABLE 31 AREAS OF UNMET CLINICAL NEED IN DES TREATMENT	66
TABLE 32 PRODUCTS IN DEVELOPMENT TO TREAT DES - PHASE III	68
TABLE 33 PRODUCTS IN DEVELOPMENT TO TREAT DES - PHASE II	68
TABLE 34 GLOBAL DES SALES OF PIPELINE PRODUCTS, THROUGH 2019 (\$ MILLIONS)	70

TABLE HEADING	PAGE NO.
TABLE 35 GLOBAL DES SALES OF APPROVED AND PIPELINE PRODUCTS, THROUGH 2019 (\$ MILLIONS)	71
TABLE 36 PRODUCTS APPROVED TO TREAT UVEITIS	75
TABLE 37 GLOBAL UVEITIS SALES OF APPROVED PRODUCTS, THROUGH 2019 (\$ MILLIONS)	76
TABLE 38 GLOBAL UVEITIS SALES OF APPROVED PRODUCTS BY DRUG CLASS, THROUGH 2019 (\$ MILLIONS)	76
TABLE 39 GLOBAL UVEITIS SALES OF APPROVED PRODUCTS BY COMPANY, THROUGH 2019 (\$ MILLIONS)	78
TABLE 40 AREAS OF UNMET CLINICAL NEED IN UVEITIS TREATMENT	79
TABLE 41 PRODUCTS IN DEVELOPMENT TO TREAT UVEITIS - PHASE III	81
TABLE 42 PRODUCTS IN DEVELOPMENT TO TREAT UVEITIS - PHASE II	81
TABLE 43 PRODUCTS IN DEVELOPMENT TO TREAT UVEITIS - PHASE I	82
TABLE 44 GLOBAL UVEITIS SALES OF PIPELINE PRODUCTS, THROUGH 2019 (\$ MILLIONS)	83
TABLE 45 GLOBAL UVEITIS SALES OF APPROVED AND PIPELINE PRODUCTS, THROUGH 2019 (\$ MILLIONS)	85
TABLE 46 LEADING OPHTHALMIC DEALS IN THE U.S. BASED ON VALUE, 2007-JULY 2015 (\$ MILLIONS)	89
TABLE 47 LEADING OPHTHALMIC DEALS IN ASIA BASED ON VALUE, 2007-2014 (\$ MILLIONS)	90
TABLE 48 LEADING OPHTHALMIC DEALS IN EUROPE BASED ON VALUE, 2007-2014 (\$ MILLIONS)	91
TABLE 49 LEADING OPHTHALMIC DEALS IN AMD BASED ON VALUE, 2007-2014 (\$ MILLIONS)	93
TABLE 50 LEADING OPHTHALMIC DEALS IN RETINOPATHY BASED ON VALUE, 2007-2014 (\$ MILLIONS)	95
TABLE 51 LEADING OPHTHALMIC DEALS IN GLAUCOMA BASED ON VALUE, 2007-2014 (\$ MILLIONS)	96
TABLE 52 RECENT ACQUISITIONS IN THE OPHTHALMIC ARENA BASED ON VALUE, 2007- JULY 2015 (\$ MILLIONS)	98

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE GLOBAL OPHTHALMIC THERAPEUTIC DRUG MARKET BY SEGMENT,2013-2019 (\$ MILLIONS)	8
FIGURE 1 STRUCTURE OF THE EYE	10
FIGURE 2 AMD ADDRESSABLE PATIENT POPULATION (NUMBERS)	11
FIGURE 3 PHYSIOLOGICAL CHANGES IN WET AND DRY AMD	13
FIGURE 4 GLOBAL MARKET SHARE OF AMD APPROVED PRODUCTS BY COMPANY, 2014 (%)	16
FIGURE 5 MECHANISM OF ACTION OF ACUCLEA'S VCMS	25
FIGURE 6 GLAUCOMA ADDRESSABLE PATIENT POPULATION (NUMBERS)	30
FIGURE 7 SCHEMATIC OF OPEN AND CLOSED ANGLE GLAUCOMA	31
FIGURE 8 PRESCRIPTION DRUG CLASSES IN THE U.S., 2013 (%)	35
FIGURE 9 PRESCRIPTION DRUG CLASSES IN EUROPE, 2013 (%)	36
FIGURE 10 PRESCRIPTION DRUG CLASSES IN JAPAN, 2010 (%)	37
FIGURE 11 GLOBAL MARKET SHARE OF GLAUCOMA APPROVED PRODUCTS BY DRUG CLASS, 2014 (%)	41
FIGURE 12 GLOBAL MARKET SHARE OF GLAUCOMA APPROVED PRODUCTS BY COMPANY, 2014 (%)	42
FIGURE 13 QUADRUPLE MODE OF ACTION OF AERIE PHARMACEUTICALS' RHOPRESSA	48
FIGURE 14 DRY EYE SYNDROME ADDRESSABLE PATIENT POPULATION (NUMBERS)	58
FIGURE 15 GLOBAL MARKET SHARE OF DES APPROVED PRODUCTS BY DRUG CLASS, 2014 (%)	62
FIGURE 16 GLOBAL MARKET SHARE OF DES APPROVED PRODUCTS BY COMPANY, 2014 (%)	64
FIGURE 17 UVEITIS ADDRESSABLE PATIENT POPULATION (NUMBERS)	73
FIGURE 18 GLOBAL MARKET SHARE OF UVEITIS APPROVED PRODUCTS BY DRUG CLASS, 2014 (%)	76
FIGURE 19 GLOBAL MARKET SHARE OF UVEITIS APPROVED PRODUCTS BY COMPANY, 2014 (%)	78
FIGURE 20 OPHTHALMIC ALLIANCE AND LICENSING DEALS BY YEAR, 2007-2014 (NO. OF DEALS)	87
FIGURE 21 OPHTHALMIC ALLIANCE AND LICENSING DEALS BY TERRITORY, 2007-2014 (NO. OF DEALS)	87
FIGURE 22 OPHTHALMIC ALLIANCES AND LICENSING DEALS BY THERAPEUTIC CATEGORY, 2007-2014 (NO. OF DEALS)	91
FIGURE 23 OPHTHALMIC MERGERS AND ACQUISITIONS BY YEAR, 2007-2014 (NUMBER)	96